Head-To-Head Survey: iBio (IBIO) vs. Its Competitors

iBio (NASDAQ:IBIO) is one of 847 publicly-traded companies in the “Biotechnology” industry, but how does it contrast to its peers? We will compare iBio to related companies based on the strength of its institutional ownership, dividends, analyst recommendations, risk, profitability, valuation and earnings.

Valuation & Earnings

This table compares iBio and its peers gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
iBio	$100,000.00	-$33.04 million	-2.34
iBio Competitors	$695.89 million	$9.64 million	-10.06

iBio’s peers have higher revenue and earnings than iBio. iBio is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Risk and Volatility

iBio has a beta of 1.29, indicating that its stock price is 29% more volatile than the S&P 500. Comparatively, iBio’s peers have a beta of 1.07, indicating that their average stock price is 7% more volatile than the S&P 500.

Profitability

This table compares iBio and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
iBio	N/A	-40.66%	-35.78%
iBio Competitors	-9,046.42%	-198.98%	-30.68%

Institutional and Insider Ownership

7.9% of iBio shares are held by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are held by institutional investors. 1.5% of iBio shares are held by company insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of current recommendations and price targets for iBio and its peers, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iBio	1	0	4	2	3.00
iBio Competitors	9772	15006	45333	1579	2.54

iBio presently has a consensus price target of $6.00, suggesting a potential upside of 652.82%. As a group, “Biotechnology” companies have a potential upside of 95.95%. Given iBio’s stronger consensus rating and higher possible upside, equities research analysts plainly believe iBio is more favorable than its peers.

Summary

iBio beats its peers on 7 of the 13 factors compared.

iBio Company Profile

iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.